New Age Alpha Advisors LLC acquired a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 63,149 shares of the biotechnology company's stock, valued at approximately $2,103,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new position in Exelixis in the fourth quarter valued at approximately $32,000. Principal Securities Inc. raised its stake in shares of Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after buying an additional 373 shares during the period. Kestra Investment Management LLC purchased a new position in shares of Exelixis during the 4th quarter valued at $39,000. Brooklyn Investment Group bought a new position in shares of Exelixis during the 3rd quarter worth $42,000. Finally, UMB Bank n.a. increased its holdings in Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 553 shares during the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts have weighed in on the stock. Royal Bank of Canada increased their target price on shares of Exelixis from $38.00 to $40.00 and gave the stock an "outperform" rating in a research report on Thursday, March 13th. BMO Capital Markets downgraded Exelixis from an "outperform" rating to a "market perform" rating and increased their target price for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. Barclays increased their target price on shares of Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 13th. Guggenheim restated a "buy" rating and set a $42.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. Finally, StockNews.com upgraded Exelixis from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $37.59.
View Our Latest Stock Analysis on EXEL
Exelixis Trading Down 1.4 %
Shares of EXEL traded down $0.51 during mid-day trading on Thursday, reaching $36.53. The company's stock had a trading volume of 488,084 shares, compared to its average volume of 2,652,329. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02. The stock has a market cap of $10.22 billion, a PE ratio of 20.64, a P/E/G ratio of 1.13 and a beta of 0.57. The company's fifty day moving average price is $35.80 and its two-hundred day moving average price is $33.48.
Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.
Insider Activity
In other Exelixis news, EVP Patrick J. Haley sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the sale, the executive vice president now owns 341,028 shares in the company, valued at approximately $13,231,886.40. The trade was a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christopher J. Senner sold 29,314 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the completion of the transaction, the chief financial officer now owns 779,607 shares in the company, valued at $28,174,996.98. This represents a 3.62 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 140,343 shares of company stock valued at $5,177,234. Insiders own 2.85% of the company's stock.
Exelixis Company Profile
(
Free Report)
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Featured Articles
Before you consider Exelixis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.
While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
